“Fluvoxamine on the other hand actually demonstrated a 12 times reduction in all-cause mortality in the Phase 3 trial. “
Actually the Lancet article
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltext
shows about 32 percent reduction in chance of death, not “12 times reduction”. This is because of the way randomized trials are conducted. You have to look at the “intention to treat” analysis. What happened the the Fluvoxamine trial was that many patients in the fluvoxamine arm of the trial died before they had finished the course of treatment. Among those who finished the entire course of treatment, there was a 12 times reduction in death. But 16 patients in the fluovoxamine arm of the trial died before they finished the treatment. Folks, please get into the weeds when reading these articles. Look at the actual trials, not the summary from “Steve Kirsch” as provided by “ransomnote”. Here’s a link to an article explaining the “intention to treat” concept in randomized trials. I just learned about this by reading this article.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654877/
That being said, fluvoxamine does seem to help, and might make you feel more relaxed as a fringe benefit.
| In the General/Chat forum, on a thread titled Do you know why there isn't an EUA for fluvoxamine? The drug works. Amazingly well. Better than anything else against COVID when given early. So why isn't there an EUA?, brookwood wrote: |
“Fluvoxamine on the other hand actually demonstrated a 12 times reduction in all-cause mortality in the Phase 3 trial. “ Actually the Lancet article shows about 32 percent reduction in chance of death, not “12 times reduction”. This is because of the way randomized trials are conducted. You have to look at the “intention to treat” analysis. What happened the the Fluvoxamine trial was that many patients in the fluvoxamine arm of the trial died before they had finished the course of treatment. Among those who finished the entire course of treatment, there was a 12 times reduction in death. But 16 patients in the fluovoxamine arm of the trial died before they finished the treatment. Folks, please get into the weeds when reading these articles. Look at the actual trials, not the summary from “Steve Kirsch” as provided by “ransomnote”. Here’s a link to an article explaining the “intention to treat” concept in randomized trials. I just learned about this by reading this article. |
"There were 17 deaths in the fluvoxamine group and 25 deaths in the placebo group in the primary intention-to-treat analysis (odds ratio [OR] 0·68, 95% CI: 0·36–1·27)."